Company profile
AI Proteins
Designing de novo miniprotein therapeutics using AI for drug discovery.
- Category
- Healthcare AI
- Headquarters
- Boston, Massachusetts
- Sells to
- Enterprise
- Business model
- Licensing
- Deployment
- Not stated
- Pricing
- Not published
- Builds own models
- Yes
- Modalities
- Other
What AI Proteins does
AI Proteins is a Boston-based biotech company focused on re-imagining protein therapeutics. They use an AI-enabled design and a high-throughput drug discovery platform to create de novo miniproteins optimized for various therapeutic applications. The company aims to build flawless medicines from first principles, unconstrained by evolution, with complete control over function, selectivity, stability, and pharmacology. Their platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. They partner with leading biopharmaceutical companies and advance their internal pipeline across a wide variety of therapeutic areas.
Key capabilities
- AI-enabled design
- High-throughput drug discovery platform
- De novo miniprotein creation
- Optimized for therapeutic applications
- Closed-loop engine for de novo protein design
- Generative AI for miniprotein design (specifying stability, affinity, pharmacology)
- Automated technologies for candidate generation
- Lab validation for structure, biophysics, and function
- AI-directed mutagenesis engine (AWESSM) for optimization and learning
- Modular
- Scalable
- Safe
- Purpose-built
- Small
- Low immunogenicity
- Hyper-stable
- Precise
- Efficacious
- Patentable
- Genetically encoded
- Chemically synthesized
- Easily concatenated
- Easily conjugated
Use cases
- Drug discovery
- Therapeutic applications
- Development of lead therapeutic candidates
- Anti-inflammatory programs
- Immune activator development
- GLP-1 agonist development
- Cancer therapeutics
- Immune cell engagers for oncology
- Inhibitors for autoimmunity
- Agonists for metabolic disease
AI approach
AI Proteins uses generative AI to design de novo miniproteins from scratch, specifying stability, affinity, and pharmacology. Their AI-directed mutagenesis engine (AWESSM) refines designs by feeding experimental results back into the models.
Tech named: Generative AI, AI-directed mutagenesis engine (AWESSM)
Industries served
- Biotechnology Research
- Biopharmaceutical
What it says sets it apart
- Designing entirely new proteins from scratch, unconstrained by evolution
- Complete control over function, selectivity, stability, and pharmacology
- Miniproteins offer enhanced tissue penetration, low-immunogenicity, and controllable pharmacokinetics
- Miniproteins are easy to synthesize, test, and validate
- High-throughput exploration of unconstrained combinatorial space, free from human bias
- Closed-loop engine for de novo protein design
- AI-directed mutagenesis engine (AWESSM) for systematic refinement
- Evidence at industrial scale with 150+ targets explored and multiple in vivo proofs-of-concept achieved
- Superior activity to semaglutide in vivo for GLP-1 agonist program
Funding rounds we track
Mission BioCapital, Santé Ventures
Cobro Ventures, Lightchain Capital
From the AI funding tracker — rounds as reported by the linked publications.
This profile was compiled from AI Proteins's own public pages in July 2026 and reflects what the company states about itself — not an endorsement or an independent audit of those claims. Facts are extracted with AI and filtered by an automated check that drops any named product, customer or certification missing from the source pages. Full method. Something out of date? Tell us.